Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a female experiencing hair loss and seeking advice on why it's difficult to regrow hair. Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned.

The conversation discusses concerns about oral minoxidil potentially aging the face by affecting collagen, questioning its systemic effects. The user has successfully used topical minoxidil for years and is hesitant to switch to oral minoxidil.

User TopBack56 and friends tried pyrilutamide (KX-826) for hair loss without experiencing negative side effects. They observed fine vellus hairs but no thick hair growth yet, and plan to add GT20029 to their regime after safety trials.

The user is experiencing severe hair loss after starting Minoxidil 5% and is seeking advice, as their hair loss worsened following a second COVID infection. Despite normal hormone and vitamin levels, the user is considering additional treatments like Ketoconazole shampoo, massages, and low-level laser therapy.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

Dihydrotestosterone (DHT) impacts various skin conditions, including Androgenetic alopecia and seborrheic dermatitis, by causing overactivity in sebaceous glands. Topical medications Tacrolimus and Clobetasol can reduce these inflammatory conditions, and treatments like RU58841, Minoxidil, and Finasteride may also be beneficial.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

The conversation is about someone experiencing continued hair loss despite using Pyrilutamide and considering the need for more time or better quality control for the treatment. Another person suggests waiting for the drug to be officially approved due to potential quality issues with current products.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

Seborrheic dermatitis can cause hair loss, and treatments like ketoconazole shampoo, topical steroids, and oral antifungals may help. Some consider using finasteride and minoxidil for hair loss despite dermatitis.

A user (seblt) who has had side effects from finasteride, minoxidil and RU58841 but is now trying pyrilutamide as a last resort, with other users providing advice and support. They have already seen some baby hairs growing after 10-14 days of treatment and will provide updates in 1-2 weeks.

A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.

Koshine 826 (Pyrilutamide) has mixed reviews, with some users experiencing side effects like insomnia and others seeing minimal results. Concerns about the company's transparency and lack of progress photos are noted.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Minoxidil may cause wrinkles and dark circles, which some users report can be mitigated by adjusting dosage. Reactions vary, and while some dismiss these side effects, others experience significant changes.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks updates on topical treatment Pyrilutamide.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Minoxidil is highly toxic to cats, and even small amounts can be fatal. The user decided against using topical minoxidil due to the risk to their cats and considered oral minoxidil and ketoconazole shampoo as alternatives.

The user treated seborrheic dermatitis and hair loss with a routine including sulfate-free tea tree oil shampoo, ketoconazole shampoo, minoxidil foam, microneedling, and supplements like Omega-3 and Vitamin-D. They experienced significant hair shedding initially but saw improvement over a year.

The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.